Drug intelligence / Profile preview

carmustine + cisplatin + cyclophosphamide + trastuzumab

Development stage: Unknown
Lead developer: Michigan State University
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Subcutaneous

Overview

This is a combination chemotherapy regimen consisting of carmustine (BCNU), cisplatin, cyclophosphamide, and trastuzumab. Carmustine is an alkylating agent that crosses the blood-brain barrier and is used to treat various malignancies including brain tumors, multiple myeloma, and lymphomas. Cisplatin is a platinum-based chemotherapy drug. Cyclophosphamide is another alkylating agent. Trastuzumab is a monoclonal antibody that targets HER2-positive cancers.

Targets

DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on carmustine + cisplatin + cyclophosphamide + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carmustine + cisplatin + cyclophosphamide + trastuzumab.

Explore the full profile